SEC Form 4 · accession 0000891293-15-000058
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Corporate Development
Period of report
Nov 4, 2015
Accepted (ET)
Nov 6, 2015 · 6:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 4, 2015 | S | 1,900 | $1.37 | D | 638,184 | D | |
| Common Stock | Nov 4, 2015 | S | 1,800 | $1.375 | D | 636,384 | D | |
| Common Stock | Nov 4, 2015 | S | 3,500 | $1.38 | D | 632,884 | D | |
| Common Stock | Nov 4, 2015 | S | 200 | $1.385 | D | 632,684 | D | |
| Common Stock | Nov 4, 2015 | S | 1,100 | $1.39 | D | 631,584 | D | |
| Common Stock | Nov 4, 2015 | S | 100 | $1.395 | D | 631,484 | D | |
| Common Stock | Nov 4, 2015 | S | 1,400 | $1.40 | D | 630,084 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan.